Open
友銘將自生技中心移轉(zhuǎn)一小分子化合物，做為腫瘤醫(yī)學(xué)開發(fā)的小分子首創(chuàng)新藥(不同藥物機(jī)制中的第一個(gè)新藥)。研發(fā)團(tuán)隊(duì)由張嘉銘博士率領(lǐng)，預(yù)期於2023年進(jìn)行人體臨床試驗(yàn)。
Through the Value-Creation project funding, Famous Biotech will be granted a small compound from DCB that is the first-in-class molecule for oncology development.
Through the Value-Creation project funding, Famous Biotech will be granted a small compound from DCB that is the first-in-class molecule for oncology development.